Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
February 27 2024 - 7:00AM
Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage
biopharmaceutical company focused on developing innovative
treatments for cancer patients, today announced that the
internationally recognized radiopharmaceutical physician, Professor
Rodney Hicks, will be the lead investigator for Monopar’s
MNPR-101-Zr Phase 1 dosimetry clinical trial in advanced cancer
patients. Professor Hicks will enroll patients at the Melbourne
Theranostic Innovation Centre (MTIC) and will use one of the
world's most sensitive clinical total-body PET/CT (positron
emission tomography–computed tomography) scanners, the Siemens
Biograph Vision Quadra, to image the targeting ability of
MNPR-101-Zr in cancer patients.
“We are very excited to have Professor Hicks as the lead
investigator for our MNPR-101-Zr clinical trial,” said Chandler
Robinson, MD, Monopar’s Chief Executive Officer. “He is a true
pioneer in the radiopharma space, having helped introduce
radiopharma agents into the clinic which are now approved globally
for neuroendocrine tumors and prostate cancer, and having installed
the first PET/CT in Australia and one of the first in the
world.”
Professor Rodney Hicks, MBBS(Hons), MD, FRACP, FICIS, FAAHMS is
the Founder, Chief Medical Officer, and Board Chair of Precision
Molecular Imaging & Theranostics Pty Ltd, the company that
operates MTIC. He is the former Director of Cancer Imaging at Peter
MacCallum Centre in Melbourne, one of Australia’s largest cancer
research centers, and has published over 650 research articles,
reviews, and commentaries. In 2023, Professor Hicks received the
Saul Hertz Award from the Society of Nuclear Medicine and Molecular
Imaging for his lifetime contribution to radionuclide therapy.
“The preclinical data that Monopar announced on this past
Thursday encourages us to translate this class of agents into the
clinical domain. MNPR-101-Zr is being developed for cancers with
very high unmet medical need, such as pancreatic cancer and triple
negative breast cancer,” said Professor Hicks. “I founded MTIC in
part to help patients gain access to promising new
radiopharmaceuticals, and the entire MTIC team is looking forward
to activating the MNPR-101-Zr trial shortly and enrolling
patients.”
Additional information about the MNPR-101-Zr Phase 1 dosimetry
clinical trial for advanced cancer patients as well as the recently
announced associated preclinical data can be found at the following
links: MNPR-101-Zr Phase 1 and Preclinical Data.
About Monopar Therapeutics Inc. Monopar Therapeutics
is a clinical-stage biopharmaceutical company focused on developing
innovative treatments for cancer patients. Monopar's pipeline
consists of Phase 1b-stage camsirubicin for the treatment of
advanced soft tissue sarcoma; Phase 1-stage MNPR-101 for
radiopharmaceutical use in advanced cancers; and an early-stage
camsirubicin analog, MNPR-202. For more information,
visit: www.monopartx.com.
Forward-Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. The words “may,”
“will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying
words. Examples of these forward-looking statements include:
that Professor Rodney Hicks will be the lead investigator on
Monopar’s MNPR-101-Zr Phase 1 dosimetry clinical trial in advanced
cancer patients; that Professor Hicks will be enrolling patients at
the Melbourne Theranostic Innovation Centre (MTIC) and will utilize
one of the world's most sensitive PET/CT; and that the MTIC team is
looking forward to activating the MNPR-101-Zr trial shortly and
enrolling patients. The forward-looking statements involve risks
and uncertainties including, but not limited to: that future
preclinical or clinical data will not be as promising as the data
to date; not initiating and enrolling the Phase 1 clinical trial;
that MNPR-101-Zr may cause unexpected serious adverse effects or
fail to image or be effective against the cancer tumors in humans;
the potential for the HREC to put the Phase 1 trial on clinical
hold at any time; and the significant general risks and
uncertainties surrounding the research, development, regulatory
approval, and commercialization of imaging agents and therapeutics.
Actual results may differ materially from those expressed or
implied by such forward-looking statements. Risks are described
more fully in Monopar's filings with the Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were
made. Monopar undertakes no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made. Any forward-looking
statements contained in this press release represent
Monopar’s views only as of the date hereof and should not be
relied upon as representing its views as of any subsequent
date.
CONTACT:
Monopar Therapeutics Inc.Investor
Relations Kim R. Tsuchimoto Chief Financial
Officer kimtsu@monopartx.com
Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics
Monopar Therapeutics (NASDAQ:MNPR)
Historical Stock Chart
From Apr 2024 to May 2024
Monopar Therapeutics (NASDAQ:MNPR)
Historical Stock Chart
From May 2023 to May 2024